Physician profile
John Albert Wetherhold
NPI 1740382290
$4,442.08
in general payments reported to CMS, 2019-2025
21 companies · $994 in 2025
The $994 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $28.93 · 2021: $190 · 2022: $1,448 · 2023: $630 · 2024: $875 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,498.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,247.18 | 2019-2023 | Acuvue |
| Bausch & Lomb Americas INC. | $851.13 | 2022-2025 | Vyzulta, Infuse, Miebo |
| Alcon Vision LLC | $498.25 | 2019-2025 | Tryptyr, Rocklatan, Precision7 |
| Abbvie INC. | $488.66 | 2023-2025 | Durysta, Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $278.83 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.53 | 2019-2021 | |
| Dompe US, INC. | $164.93 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $162.49 | 2023-2025 | Cequa |
| Coopervision INC. | $119.92 | 2019-2022 | |
| Oyster Point Pharma, INC. | $99.29 | 2022-2025 | Tyrvaya |
| Thea Pharma INC. | $77.33 | 2023-2025 | Iyuzeh |
| Harrow Eye, LLC | $45.80 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $33.12 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $32.54 | 2021-2023 | |
| Rayner Intraocular Lenses Limited | $28.03 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $27.85 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $26.26 | 2021 | |
| Plexus Optix, INC. | $24.79 | 2019 | |
| Sight Sciences, INC. | $19.57 | 2025 | Tearcare System |
| Amgen INC. | $19.41 | 2025 | Tepezza |
| Optos, INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wetherhold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.